UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset known as bepranemab.
Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.
The scene was set for the first game of the 2024 Pacific Championships on Friday night with a powerful Sipi Tau from the Tongan team. Veteran hooker Siliva Havili led the way for Tonga as the ...